Literature DB >> 32505416

Relation of Copeptin with Diabetic and Renal Function Markers Among Patients with Diabetes Mellitus Progressing Towards Diabetic Nephropathy.

Tooba Noor1, Farina Hanif2, Zareen Kiran3, Rehana Rehman4, Muhammad Tassaduq Khan5, Zeba Haque6, Kelash Nankani1.   

Abstract

BACKGROUND: Arginine vasopressin (AVP) plays an important role in the pathophysiology of Diabetes Mellitus (DM) and its related complications like diabetic nephropathy. Copeptin is considered as a reliable surrogate biomarker of AVP. If raised levels of copeptin in diabetic patients are detected earlier, prognosis of DM can be improved by timely modulating the treatment strategy. AIMS OF THE STUDY: The study is therefore planned to assess copeptin levels in different groups of DM and in healthy controls to suggest a better and reliable biomarker for progressive stages of DM.
METHODS: Subjects were recruited as controls, pre diabetes, DM without nephropathy and diabetic nephropathy. Serum copeptin levels were measured by ELISA. While, Blood Urea Nitrogen (BUN), creatinine, Glycosylated Hemoglobin (HbA1c) and spot urinary albumin creatinine ratio (UACR) were done using spectrophotometry. Statistical analysis was done using ANOVA and Pearson's correlation tests on SPSS.
RESULTS: The average copeptin levels were 215.096 pg/mL. Copeptin levels were significantly elevated in subjects with positive family history of DM (p = 0.025), levels were also raised in pre diabetes kpatients (252.85 pg/mL) as compared to other groups. Copeptin levels were also correlated with HbA1c r = 0.171 (p = 0.101), BUN r = 0.244 (p = 0.007), creatinine r = 0.215 (p = 0.018), UACR r = 0.375 (p = <0.001) and GFR r = 0.215 (p = <0.019).
CONCLUSION: The significant correlation of copeptin with diabetic and renal biomarkers, along with its positive association with family history of DM support its' role as an early and reliable biomarker of DM and its associated nephropathy.
Copyright © 2020 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Copeptin; Diabetes mellitus; Diabetic nephropathy; Glomerular filtration rate; Pre diabetes; Vasopressin

Mesh:

Substances:

Year:  2020        PMID: 32505416     DOI: 10.1016/j.arcmed.2020.05.018

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  5 in total

Review 1.  The role of copeptin in kidney disease.

Authors:  Pedro Iglesias; Ramona A Silvestre; María José Fernández-Reyes; Juan J Díez
Journal:  Endocrine       Date:  2022-10-15       Impact factor: 3.925

2.  Effects of Huangqi Liuyi Decoction in the Treatment of Diabetic Nephropathy and Tissue Distribution Difference of its Six Active Constituents Between Normal and Diabetic Nephropathy Mouse Models.

Authors:  Qun Wang; Ya Shi; Zengguang Wu; Xinli Song; Jinfang Luo; Hong Yang; Xiaolan Chen; Xingde Liu
Journal:  Front Pharmacol       Date:  2022-06-21       Impact factor: 5.988

3.  Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.

Authors:  Chaterina Sujana; Jochen Seissler; Jens Jordan; Wolfgang Rathmann; Wolfgang Koenig; Michael Roden; Ulrich Mansmann; Christian Herder; Annette Peters; Barbara Thorand; Cornelia Then
Journal:  Cardiovasc Diabetol       Date:  2020-10-16       Impact factor: 9.951

4.  Relationship between serum cystatin-c and coronary lesion severity in coronary artery disease patients with a normal glomerular filtration rate.

Authors:  Junqiang Pan; Xifeng Sun; Pengjie Zhang; Haichao Chen; Jing Lin
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

Review 5.  Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease.

Authors:  Christodoula Kourtidou; Maria Stangou; Smaragdi Marinaki; Konstantinos Tziomalos
Journal:  Int J Mol Sci       Date:  2021-10-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.